Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Syndesi Therapeutics

Request full access

Developer of a series of novel, procognitive SV2A modulators

Wavre, BelgiumFounded 2018Biotech & Life Sciences

About Syndesi Therapeutics

Syndesi Therapeutics was a clinical-stage biotechnology company headquartered in Louvain-la-Neuve, Belgium, dedicated to developing novel treatments for cognitive impairment. Established in 2017 as a corporate spinoff from the biopharmaceutical major UCB, Syndesi focused on a unique class of small molecules that modulate the synaptic vesicle protein 2A (SV2A). Its lead asset, SDI-118, was designed to enhance synaptic efficiency directly at the nerve terminal, addressing the underlying synaptic dysfunction common in neurodegenerative and neuropsychiatric conditions such as Alzheimer’s disease and major depression.

The company’s rapid growth trajectory culminated in a landmark acquisition by AbbVie in March 2022. Valued at up to $1 billion, the deal included a $130 million upfront payment with potential milestone payments reaching $870 million, validating the high strategic value of Syndesi’s "first-in-class" mechanism. Prior to this exit, Syndesi had secured a €17 million Series A backed by a robust syndicate including Novo Holdings, Fountain Healthcare Partners, and Johnson & Johnson Innovation (JJDC), positioning it as a standout example of successful corporate venture building in the European life sciences sector.

Syndesi Therapeutics serves as a prime case study of effective technology transfer between a large pharmaceutical incumbent (UCB) and an agile startup structure. By rapidly advancing the SDI-118 program through early clinical validation (Phase 1b), the team successfully attracted a global heavy hitter in neuroscience, delivering a significant return to its investors while accelerating the potential delivery of new cognitive therapies to patients.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
10
Open positions
None listed
Dealroom signal
28.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Drug Development, Sustainable Development Goals, Biotech and Pharma, Longevity, proteomics, DT and LS, science-based
Technology
Hardware
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Mar 2022 $130M $130M AbbVie ↗
SERIES AEquity / VC Sep 2020 $6.6M $26M Fountain Healthcare Partners · V-Bio Ventures · UCB Ventures · Novo Seeds —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Syndesi Therapeutics website traffic

Latest recorded traffic for Syndesi Therapeutics is 140 monthly website visits, down 98.2% over the last three months. Syndesi Therapeutics's team grew 0% over the past year.

Latest monthly visits140 3-month web change-98.2% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Syndesi Therapeutics in the Wavre ecosystem

Live from Dealroom

The Syndesi Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Novo Ventures
  • Fountain Healthcare Partners
  • Wallonie Entreprendre
  • Johnson & Johnson Innovation
  • Vives Partners
  • Novo Seeds
  • V-Bio Ventures
  • UCB Ventures

Series B and later1 investor entered at this stage

  • UCB

Other known investors4 additional known investors

  • AbbVie
  • Bioqube Ventures
  • Novo Holdings
  • WE Venture
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇧🇪 Belgium · Wavre HQ
Book a demo for the full country breakdown

See Syndesi Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.